David A. Siegel Pro Qr Therapeutics N.V. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Pro Qr Therapeutics N.V. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 140,300 shares of PRQR stock, worth $267,973. This represents 0.0% of its overall portfolio holdings.
Number of Shares
140,300
Previous 61,000
130.0%
Holding current value
$267,973
Previous $81,000
253.09%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding PRQR
# of Institutions
65Shares Held
41.2MCall Options Held
26KPut Options Held
0-
Adage Capital Partners Gp, L.L.C. Boston, MA6.6MShares$12.6 Million0.02% of portfolio
-
Privium Fund Management B.V.5MShares$9.55 Million2.17% of portfolio
-
Affinity Asset Advisors, LLC New York, NY3.5MShares$6.68 Million1.2% of portfolio
-
Morgan Stanley New York, NY3.08MShares$5.89 Million0.0% of portfolio
-
Sio Capital Management, LLC New York, NY2.08MShares$3.96 Million2.02% of portfolio
About ProQR Therapeutics N.V.
- Ticker PRQR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,362,096
- Market Cap $136M
- Description
- ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...